Schizophrenia Clinical Trial
Official title:
Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
The goal of this project, which has not changed, is to evaluate the statewide implementation
of a two-component intervention (health promotion plus academic detailing) with respect to
consumer outcomes and changes in provider prescribing. The intervention, called In SHAPE, is
delivered to people with serious mental illness (SMI) by two community mental health clinics
(CMHCs). These CMHCs are compared to two CMHCs delivering usual-care to individuals with
SMI. The specific aims of this study are:
1. Evaluate person-level and provider-level outcomes including: (a) consumer health
behaviors, health indicators, mental health indicators, and acute health service
utilization, (b) provider prescribing practices and program fidelity, and (c) program
costs.
2. Evaluate system-level outcomes including: (a) consumer health behaviors and health
indicators, (b) provider prescribing and program fidelity, and (c) acute services use.
Status | Completed |
Enrollment | 120 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Age 21 or older - Serious mental illness defined by (a) an axis I diagnosis of major depression, bipolar disorder, schizoaffective disorder, or schizophrenia, (b) moderate impairment across multiple areas of psychological functioning, or (c) Global Assessment of Functioning (GAF) score less than 61 - Able to provide voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator - Poor fitness as indicated by BMI > 25 or failure to adhere to the US Department of Health and Human Services Physical Activity Guidelines for Americans, i.e., at least 2.5 hr/week of moderate or 75 min/week of vigorous activity in more than one session - Medical clearance for participation in an exercise and dietary modification program by a physician, physician assistant, or nurse practitioner - An expressed willingness to participate in a diet and exercise program - Currently taking an atypical antipsychotic medication - Able to walk a city block - Responsible for choice of foods and how they are prepared Exclusion Criteria: - Currently residing in a nursing home or group home - Terminal physical illness expected to result in the death of the study subject within one year - Primary diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by a Mini-Mental State Examination (MMSE) score < 24 - Inability to speak and understand English - Pregnancy |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United States | West Central Behavioral Health | Lebanon | New Hampshire |
United States | Mental Health Center of Greater Manchester | Manchester | New Hampshire |
United States | Greater Nashua Mental Health Center at Community Council | Nashua | New Hampshire |
United States | Center for Life Management | Salem | New Hampshire |
Lead Sponsor | Collaborator |
---|---|
Dartmouth-Hitchcock Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in exercise capacity | Change in exercise capacity measured by the 6-minute walk test. | baseline, 6-, 12-, and 24-months | No |
Secondary | Self-reported physical activity | Change in self-reported physical activity measured with International Physical Activity Questionnaire (IPAQ) | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in dietary behaviors | Change in dietary behaviors measured with the Block Food Frequency Questionnaire (FFQ)21 and the Questionnaire on Eating and Weight Patterns (QEWP). | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in stage of change | Change in stage of change measured with the Weight Loss Behavior-Stage of Change Scale (WLB-SOC) 23 to assess stage of change for engaging in healthy eating and exercise behaviors. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in eating behavior | Change in eating behavior measured with the Dutch Eating Behavior Questionnaire which includes 13 questions assessing emotional eating and 10 questions related to external eating behaviors | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in physical measurement | Including height, weight, pulse, CO2 level, lung capacity from spirometer, variables from impedance measure such as percentage of body fat and percentage of lean muscle mass, cholesterol and triglyceride levels from finger stick (cholesterol data for data points that have already passed will be collected from participants' clinic and hospital records), waist circumference: BMI derived from height and weight. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in smoking and substance use | Change in smoking and substance use measured by questions developed for R01DA021245, "Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia," and questions from the "Quit Smoking Decision Aid"( developed by Ferron and Brunette, CPHS # 180) to ascertain smoking frequency, quantity, and cessation attempts | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in psychological functioning (depression, negative symptoms, and self-efficacy). | Change in psychological functioning measured by the Center for Epidemiologic Studies Depression Scale,Scale to Assess Negative Symptoms,16 and the Self-Rated Abilities for Health Practices Scale will be used to assess these constructs. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in social functioning | Change in social functioning measured by the Social Network Questionnaire and Lehman Social Contact Scale. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in family contact | Change in family contact measured by the Revised Family Contact Questionnaire. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in social support and eating habits | Change in the impact of social support on eating habits measured by the Social Support and Eating Habits Survey | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in social support and exercise | Change in the impact of social support on exercise behaviors measured by the Social Support and Exercise Survey | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in comorbid medical illness | Change in comorbid medical illness measured using a medical problems list. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in medications | Change in medications measured by gathering information from participants about type, dose, and frequency of all prescribed medications. | baseline, 6-, 12-, and 24-months | No |
Secondary | Change in service use | Measured change in service use based on a measured designed for the In SHAPE studies to collect self-reported use of emergency services and hospitalizations. | baseline, 6-, 12-, and 24-months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |